Sabrina McCrear

A study using Mendelian randomization found higher BMI and IBD have causal links to hidradenitis suppurativa risk.

A novel phase 1 trial explores the safety and efficacy of targeted radiotherapy for leptomeningeal metastases in breast cancer patients.

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.

With ACA subsidies expiring, experts warn coverage losses could worsen access to behavioral health care and emergency department strains.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.

Our top breast cancer stories in 2025 covered FDA approvals, new and failed therapies, screening gaps, and policy factors shaping treatment access and outcomes.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

Oncology leaders warn that declining reimbursements and policy gaps threaten patient access and drive inequities in cancer care.

Pediatric atopic dermatitis advances, ruxolitinib safety, IgE insights, and more at the Society for Pediatric Dermatology (SPD) 2025 meeting.

Clinicians and health system leaders met in Cleveland, Ohio, on October 23, 2025, to share improvements to value-based care in diabetes and chronic kidney disease.

Democrats move to extend ACA subsidies as enrollment closes, leaving consumers uncertain about premiums, coverage, and alternative health options.

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients.

ICHRAs may help employers and employees manage rising premiums and the loss of extended tax credits, according to expert insights from Ben Light.

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.

ACIP delayed the vote on the hepatitis B vaccine schedule amid ongoing controversy and misinformation surrounding vaccine safety and infant immunization.

Polarized dermatoscopes produced higher-quality teledermatology images but at greater cost, raising questions about feasibility and equitable access.

Guideline-recommended HF therapies do not improve major outcomes in Chagas disease, though sacubitril/valsartan improved NT-proBNP levels, new data show.

With ACA subsidies ending in 2025, Ben Light explains how rising premiums may push individuals toward ICHRAs and reshape employer health coverage strategy.

A new study shows fee-for-service care is linked to higher odds of low-value surgery, suggesting salaried models may reduce unnecessary procedures.

New research shows immigrant children face higher odds of unmet medical needs as federal and state coverage rules narrow.

With ACA subsidies and key CMS payment models ending in 2025, premiums are set to rise, shifting costs to consumers and employers.

Non-DNMT3A CHIP subtypes raised heart failure risk in a recent analysis, offering new insights for prevention and targeted management.

A large cohort study found adolescents and young adults starting TMP-SMX faced a higher 30-day risk of acute respiratory failure than those on other antibiotics.

Phase 3 ADORING data show tapinarof improves skin, itch, and sleep in children with atopic dermatitis, with similar efficacy and safety in those with comorbidities.

Phase 3 ADORING data show tapinarof cream delivers early, consistent skin, itch, and sleep improvements in children with atopic dermatitis, with low adverse event rates.

Scientists restored the CCNA2 gene in adult human heart cells, enabling them to divide and form new functional cardiomyocytes—advancing heart repair therapies.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.